☆ 4.5 Review

Pharmacokinetic considerations for angiogenesis inhibitors used to treat hepatocellular carcinoma: an overview

EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2023)

Related references

Note: Only part of the references are listed.

Article Oncology

Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population

Andrea Casadei-Gardini et al.

Summary: This retrospective multi-center study compared the clinical efficacy and safety of lenvatinib and atezolizumab plus bevacizumab as a first-line treatment for unresectable HCC. The results showed that atezolizumab plus bevacizumab did not have a significant survival advantage over lenvatinib overall. However, lenvatinib had a higher overall survival rate in patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease, while atezolizumab plus bevacizumab had a higher overall survival rate in patients with viral hepatitis. After adjusting for population, atezolizumab plus bevacizumab provided better safety profile for most adverse events.

EUROPEAN JOURNAL OF CANCER (2023)

Add to Collection

Article Pharmacology & Pharmacy

Regorafenib loaded self-assembled lipid-based nanocarrier for colorectal cancer treatment via lymphatic absorption

Dengning Xia et al.

Summary: By developing a self-assembled lipid-based nanocarrier, we were able to enhance the oral absorption and anti-colorectal cancer efficacy of a chemotherapy drug. This nanocarrier utilizes the lymphatic absorption pathway and shows promising results in the treatment of colorectal cancer.

EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2023)

Add to Collection

Article Gastroenterology & Hepatology

Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma

Mathew Vithayathil et al.

Summary: This study investigated the impact of BMI on the safety and efficacy of Atezo/Bev in unresectable HCC patients. The results showed no significant differences between overweight and non-overweight patients in terms of survival rates, progression-free survival, overall response rate, and disease control rate. However, overweight patients had a higher risk of treatment-related fatigue and thrombosis.

HEPATOLOGY INTERNATIONAL (2023)

Add to Collection

Review Gastroenterology & Hepatology

Are patients with hepatocellular carcinoma and portal vein tumour thrombosis candidates for liver transplantation?

Arvinder Soin et al.

Summary: In this debate, the authors discuss the suitability of liver transplantation for patients with hepatocellular carcinoma and portal vein tumor thrombosis. The argument for liver transplantation is based on the belief that it provides greater clinical benefits in terms of survival outcomes compared to palliative systemic therapy after successful downstaging treatment. The counterargument is that the evidence for liver transplantation in this setting is limited, and expected survival in these patients may still be lower than the accepted thresholds for liver transplantation.

JOURNAL OF HEPATOLOGY (2023)

Add to Collection

Article Oncology

Unveiling the therapeutic potential of cabozantinib-loaded poly D,L-lactic-co-glycolic acid and polysarcosine nanoparticles in inducing apoptosis and cytotoxicity in human HepG2 hepatocellular carcinoma cell lines and in vivo anti-tumor activity in SCID female mice

Sankha Bhattacharya et al.

Summary: The study developed a nano-based drug delivery system for hepatocellular carcinoma (HCC) using cabozantinib (CNB). The CNB-loaded nanoparticles showed antiproliferative and proapoptotic effects on liver cancer cells.

FRONTIERS IN ONCOLOGY (2023)

Add to Collection

Article Oncology

The impact of proton-pump inhibitors administered with tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma

Sebastiano Buti et al.

Summary: Tyrosine kinase inhibitors (TKIs) are crucial for treating metastatic renal cell carcinoma (mRCC). However, the concurrent use of TKIs with proton-pump inhibitors (PPIs) can have adverse effects on treatment outcomes. A retrospective study in Italy found that the concurrent use of PPIs significantly reduced progression-free survival (PFS) and overall survival (OS) in mRCC patients treated with pazopanib or cabozantinib. Furthermore, PPI use also impacted treatment toxicity and compliance. Therefore, the indiscriminate use of PPIs should be avoided and patients requiring gastroprotective therapy should be carefully selected.

ANTI-CANCER DRUGS (2023)

Add to Collection

Article Gastroenterology & Hepatology

Survival outcomes from Atezolizumab plus Bevacizumab versus Lenvatinib versus Sorafenib in Child Pugh B unresectable hepatocellular carcinoma patients

Margherita Rimini et al.

JOURNAL OF HEPATOLOGY (2023)

Add to Collection

Article Oncology

Adaptation of lenvatinib treatment in patients with hepatocellular carcinoma and portal vein tumor thrombosis

Takanori Mukozu et al.

Summary: The study aimed to clarify the adaptation of lenvatinib treatment in patients with HCC and PVTT. It found that patients with Vp4 had a worse prognosis than those with Vp3, with a significant increase in Child-Pugh score at 2 months. Patients with major PVTT had a poor prognosis if the degree of occlusion of the portal trunk was 70% or more, and portal blood flow was significantly decreased after lenvatinib administration.

CANCER CHEMOTHERAPY AND PHARMACOLOGY (2022)

Add to Collection

Article Gastroenterology & Hepatology

Optimizing systemic therapy for advanced hepatocellular carcinoma: the key role of liver function

Giuseppe Cabibbo et al.

Summary: The number of effective systemic therapies for advanced hepatocellular carcinoma is increasing rapidly, with immunotherapy leading to improved survival outcomes. However, many patients still receive tyrosine kinase inhibitors due to contraindications to immune checkpoint inhibitors. Maintaining optimal liver function and managing hepatic decompensation are crucial in defining the treatment sequence.

DIGESTIVE AND LIVER DISEASE (2022)

Add to Collection

Article Chemistry, Physical

Improving regorafenib's organ target precision via nano-assembly to change its delivery mode abolishes chemoresistance and liver metastasis of colorectal cancer

Jia Liu et al.

Summary: Regorafenib nanodrug, fabricated with indocyanine green, overcomes the limitations of regorafenib's low bioavailability and improves its therapeutic efficacy in advanced CRC. The nanodrug significantly enhances regorafenib's tumor inhibiting efficacy and extends survival in preclinical CRC models, showing potential for clinical translation.

JOURNAL OF COLLOID AND INTERFACE SCIENCE (2022)

Add to Collection

Article Gastroenterology & Hepatology

Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma

Ann-Lii Cheng et al.

Summary: The study demonstrated that atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma patients led to improved survival outcomes. After updated analysis, atezolizumab plus bevacizumab maintained its position as the first-line treatment option for advanced hepatocellular carcinoma.

JOURNAL OF HEPATOLOGY (2022)

Add to Collection

Article Oncology

Safety and efficacy of cabozantinib for patients with advanced hepatocellular carcinoma who advanced to Child-Pugh B liver function at study week 8: a retrospective analysis of the CELESTIAL randomised controlled trial

Anthony B. El-Khoueiry et al.

Summary: This retrospective analysis evaluated the efficacy of cabozantinib in patients with advanced hepatocellular carcinoma (HCC) and Child-Pugh B liver cirrhosis. The results showed that cabozantinib improved overall survival and progression-free survival in these patients, with a safety profile consistent with the overall population.

BMC CANCER (2022)

Add to Collection

Article Gastroenterology & Hepatology

Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study

Antonio D'Alessio et al.

Summary: This study confirms the reproducible safety and efficacy of AtezoBev in routine clinical practice. Patients with impaired liver function (CP-B) showed comparable tolerability to those with normal liver function (CP-A), indicating the need for prospective evaluation in this specific population.

HEPATOLOGY (2022)

Add to Collection

Review Gastroenterology & Hepatology

BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update

Maria Reig et al.

Summary: There have been significant advances in the treatment strategies for hepatocellular carcinoma since the last update in 2018. However, some interventions still lack sufficient data for clinical incorporation, and personalized clinical management requires consideration of multiple parameters.

JOURNAL OF HEPATOLOGY (2022)

Add to Collection

Article Oncology

Influence of schisantherin A on the pharmacokinetics of lenvatinib in rats and its potential mechanism

Yanjun Cui et al.

Summary: This study showed that STA increased the bioavailability of LEN, possibly by inhibiting P-gp in the intestine and thereby increasing systemic absorption of LEN. Therefore, careful monitoring must be conducted when the two drugs are used in combination.

JOURNAL OF GASTROINTESTINAL ONCOLOGY (2022)

Add to Collection

Article Oncology

Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study

Claudia Angela Maria Fulgenzi et al.

Summary: This study confirms the reproducible safety and efficacy of atezolizumab plus bevacizumab in routine clinical practice for patients with unresectable hepatocellular carcinoma. The presence of portal vein tumor thrombosis (PVTT) and higher ALBI grade are indicators of poorer survival in patients who meet the Child-Pugh-A criteria.

EUROPEAN JOURNAL OF CANCER (2022)

Add to Collection

Article Pharmacology & Pharmacy

Discordance Between Child-Pugh and National Cancer Institute Classifications for Hepatic Dysfunction: Implications on Dosing Recommendations for Oncology Compounds

Mohamed Elmeliegy et al.

Summary: This study evaluated the discordance between the Child-Pugh classification and NCIc in patients with hepatic impairment, and the impact on dosing recommendations. The findings showed differences in PK analyses and suggested the need for consistency in classification systems for dosing decisions.

JOURNAL OF CLINICAL PHARMACOLOGY (2021)

Add to Collection

Article Oncology

FDA Supplemental Approval Summary: Lenvatinib for the Treatment of Unresectable Hepatocellular Carcinoma

Abhilasha Nair et al.

Summary: The FDA approved lenvatinib for first-line treatment of unresectable hepatocellular carcinoma based on the REFLECT trial, which showed noninferiority to sorafenib in terms of overall survival and statistically significant improvements in progression-free survival. Lenvatinib-treated patients had similar survival, more responses, and longer time to progression compared to those receiving sorafenib, but experienced more serious side effects. Lenvatinib is an effective option for previously untreated HCC patients.

ONCOLOGIST (2021)

Add to Collection

Article Medicine, General & Internal

Hepatocellular carcinoma

Josep M. Llovet et al.

Summary: Liver cancer, particularly hepatocellular carcinoma (HCC), poses a significant global health challenge with rising incidence projected to exceed 1 million cases by 2025. Infection by hepatitis B and C viruses remains a major risk factor for HCC, while non-alcoholic steatohepatitis is emerging as a more common risk factor in Western countries. Advances in systemic therapies for HCC, including immunotherapies and targeted therapies, are expected to revolutionize the management of this disease.

NATURE REVIEWS DISEASE PRIMERS (2021)

Add to Collection

Article Gastroenterology & Hepatology

Systemic treatment of hepatocellular carcinoma: An EASL position paper

Jordi Bruix et al.

Summary: Significant advances have been made in the systemic treatment of hepatocellular carcinoma in the last 5 years, with new drugs and treatment strategies emerging. Prolonged survival exceeding 2 years is expected in most patients, and selecting the right medication based on patient characteristics and preferences is crucial for sound therapeutic decisions.

JOURNAL OF HEPATOLOGY (2021)

Add to Collection

Article Oncology

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Hyuna Sung et al.

Summary: The global cancer burden in 2020 saw an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths. Female breast cancer surpassed lung cancer as the most commonly diagnosed cancer, while lung cancer remained the leading cause of cancer death. These trends are expected to rise in 2040, with transitioning countries experiencing a larger increase compared to transitioned countries due to demographic changes and risk factors associated with globalization and a growing economy. Efforts to improve cancer prevention measures and provision of cancer care in transitioning countries will be crucial for global cancer control.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

Add to Collection

Article Oncology

The Effect of Concomitant Proton Pump Inhibitor and Cabozantinib on the Outcomes of Patients with Metastatic Renal Cell Carcinoma

Elie Rassy et al.

Summary: This study investigated the impact of PPI use on the efficacy, safety, and residual concentration of cabozantinib in patients with mRCC. The results showed that PPI use did not significantly affect the outcomes, adverse events, or drug concentration of cabozantinib in mRCC patients.

ONCOLOGIST (2021)

Add to Collection

Article Biophysics

Self-assembled phospholipid-based mixed micelles for improving the solubility, bioavailability and anticancer activity of lenvatinib

Shuangshuang Zhang et al.

Summary: In this study, LFT-loaded soy phospholipid and sodium glycocholate mixed micelles (LFT-MMs) were prepared to enhance the solubility and oral bioavailability of lenvatinib. The optimized LFT-MMs showed significant improvements in solubility, encapsulation efficiency, stability, and biocompatibility. In vitro and in vivo experiments demonstrated enhanced antitumor activity and relative bioavailability of LFT-MMs compared to the original form of lenvatinib. These findings suggest that LFT-MMs are promising formulations for lenvatinib oral delivery.

COLLOIDS AND SURFACES B-BIOINTERFACES (2021)

Add to Collection

Article Pharmacology & Pharmacy

Baicalin Enhanced Oral Bioavailability of Sorafenib in Rats by Inducing Intestine Absorption

Jingyao Wei et al.

Summary: This study aimed to characterize the pharmacokinetic changes of sorafenib (SOR) when coadministered with baicalin (BG) in rats. The results showed that coadministration with BG significantly increased the oral bioavailability of SOR in rats. Further research demonstrated that BG had no significant inhibitory effects on the metabolism of SOR.

FRONTIERS IN PHARMACOLOGY (2021)

Add to Collection

Review Immunology

Microbiome Crosstalk in Immunotherapy and Antiangiogenesis Therapy

Xueting Wan et al.

Summary: The human body and its microbiome play vital roles in health, particularly in cancer occurrence and treatment. Adjusting microbial abundance may enhance treatment effectiveness. Studying the interaction between intestinal microbiota and the immune system in cancer pathogenesis and treatment can further advance research in this field.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Article Gastroenterology & Hepatology

Resubclassification and clinical management for Barcelona Clinic Liver Cancer Stage C hepatocellular carcinoma

Chih-Wen Lin et al.

Summary: This study established a new subclassification system for BCLC-C HCC, dividing patients into C0 to C4 sub-stages, to better predict overall survival and tailor therapy.

HEPATOLOGY INTERNATIONAL (2021)

Add to Collection

Article Gastroenterology & Hepatology

Lenvatinib as First-line Treatment of Hepatocellular Carcinoma in Patients with Impaired Liver Function in Advanced Liver Cirrhosis: Real World Data and Experience of a Tertiary Hepatobiliary Center

Lidia-Sabina Cosma et al.

Summary: Lenvatinib shows similar tolerability and toxicity in patients with hepatocellular cancer, with better survival benefits observed in patients with Child-Pugh class A and B liver cirrhosis.

JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Lentinan as a natural stabilizer with bioactivities for preparation of drug-drug nanosuspensions

Zili Suo et al.

Summary: The study of using drug-drug nanosuspensions of regorafenib and lentinan showed that the nanosuspensions had a small particle size of approximately 200 nm, uniform distribution, and strong stability. It demonstrated the potential of lentinan as a natural stabilizer for drug nanosuspensions, which can reduce drug toxicity, enhance oral anticancer activity, and improve drug bioavailability. This new form of combination therapy has the advantages of reducing the number of drugs taken by patients and improving compliance.

INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Nanotechnology of Tyrosine Kinase Inhibitors in Cancer Therapy: A Perspective

Eleonora Russo et al.

Summary: Nanotechnology plays a crucial role in modern cancer therapy, improving drug penetration into tumor tissues, extending blood circulation times, reducing side effects, and minimizing drug accumulation in healthy tissues. Developing new nanoparticle systems for small molecule tyrosine kinase inhibitors is essential to enhance drug solubility and reduce toxicity, especially for first-line cancer therapies.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Add to Collection

Article Chemistry, Medicinal

Bioequivalence and Pharmacokinetic Evaluation of Two Oral Formulations of Regorafenib: An Open-Label, Randomised, Single-Dose, Two-Period, Two-Way Crossover Clinical Trial in Healthy Chinese Volunteers Under Fasting and Fed Conditions

Qian Zhang et al.

Summary: The study demonstrated that two formulations of 40 mg Regorafenib were bioequivalent under fasting and fed conditions in healthy Chinese volunteers, with similar and generally good safety profiles.

DRUG DESIGN DEVELOPMENT AND THERAPY (2021)

Add to Collection

Article Oncology

Atezolizumab and Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma: Pharmacokinetic and Safety Assessments Based on Hepatic Impairment Status and Geographic Region

Colby S. Shemesh et al.

Summary: The study evaluated the pharmacokinetics and safety of unresectable hepatocellular carcinoma patients receiving first-line atezolizumab + bevacizumab, showing that varying levels of hepatic impairment and geographic regions influenced drug concentrations. However, the overall results indicated considerable exposure overlap across groups, with treatment being tolerable in all groups.

LIVER CANCER (2021)

Add to Collection

Article Oncology

Novel Microcrystal Formulations of Sorafenib Facilitate a Long-Acting Antitumor Effect and Relieve Treatment Side Effects as Observed With Fundus Microcirculation Imaging

Junxiao Wang et al.

Summary: The study developed a novel microcrystalline formulation of sorafenib, which could achieve sustainable release and long-acting effect in HCC tumors while alleviating side effects.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection

Review Oncology

Portal Vein Tumor Thrombosis and Hepatocellular Carcinoma - The Changing Tides

Abdul Rehman Khan et al.

Summary: Portal vein involvement is a feared complication of HCC, with treatment options including a combination of drugs and other modalities depending on the individual patient. While there are various therapeutic options available, the quest for the ideal combination therapy and sequence remains unanswered.

JOURNAL OF HEPATOCELLULAR CARCINOMA (2021)

Add to Collection

Review Medicine, Research & Experimental

Current status of sorafenib nanoparticle delivery systems in the treatment of hepatocellular carcinoma

Fan-Hua Kong et al.

Summary: Hepatocellular carcinoma (HCC) is the most common type of liver cancer and has high resistance to traditional chemotherapy. Sorafenib, an oral kinase inhibitor, has shown improved survival rates for advanced liver cancer patients, but its clinical application is limited by poor solubility and low bioavailability. Nanoparticles have been explored to enhance the therapeutic efficacy of sorafenib in treating HCC, offering new hope for liver cancer treatment.

THERANOSTICS (2021)

Add to Collection

Article Oncology

The effect of proton pump inhibitors on survival outcomes in advanced hepatocellular carcinoma treated with sorafenib

Warit Ruanglertboon et al.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2020)

Add to Collection

Article Gastroenterology & Hepatology

Assessment of lenvatinib treatment for unresectable hepatocellular carcinoma with liver cirrhosis

Shohei Komatsu et al.

HPB (2020)

Add to Collection

Article Medicine, General & Internal

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Richard S. Finn et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Review Health Care Sciences & Services

Pharmacogenomics, Pharmacokinetics and Circulating Proteins As Biomarkers for Bevacizumab Treatment Optimization in Patients with Cancer: A Review

Apostolos Papachristos et al.

JOURNAL OF PERSONALIZED MEDICINE (2020)

Add to Collection

Article Gastroenterology & Hepatology

Pharmacokinetics and pharmacogenetics of sorafenib in patients with hepatocellular carcinoma: Implications for combination trials

Alvaro Diaz-Gonzalez et al.

LIVER INTERNATIONAL (2020)

Add to Collection

Article Pharmacology & Pharmacy

Preparation and characterization of sorafenib-loaded microprecipitated bulk powder for enhancing oral bioavailability

Ju-Hwan Park et al.

INTERNATIONAL JOURNAL OF PHARMACEUTICS (2020)

Add to Collection

Article Oncology

Overweight is associated with better prognosis in metastatic colorectal cancer patients treated with bevacizumab plus FOLFOX chemotherapy

Bozena Cybulska-Stopa et al.

WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY (2020)

Add to Collection

Article Pharmacology & Pharmacy

Minimal impact of hepatic and renal impairment on plasma protein binding of lenvatinib, and identification of its major plasma binding protein

Yuji Mano et al.

BIOPHARMACEUTICS & DRUG DISPOSITION (2019)

Add to Collection

Review Gastroenterology & Hepatology

Treatment of hepatocellular carcinoma in patients with portal vein tumor thrombosis: Beyond the known frontiers

Lucia Cerrito et al.

WORLD JOURNAL OF GASTROENTEROLOGY (2019)

Add to Collection

Review Gastroenterology & Hepatology

Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma

Elena De Mattia et al.

WORLD JOURNAL OF GASTROENTEROLOGY (2019)

Add to Collection

Article Pharmacology & Pharmacy

Influence of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of Regorafenib: A Randomized Crossover Pharmacokinetic Study

Femke M. de Man et al.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2019)

Add to Collection

Article Gastroenterology & Hepatology

Epidemiology and Management of Hepatocellular Carcinoma

Laura Kulik et al.

GASTROENTEROLOGY (2019)

Add to Collection

Article Oncology

Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial

Andrew X. Zhu et al.

LANCET ONCOLOGY (2019)

Add to Collection

Article Pharmacology & Pharmacy

Lenvatinib mesylate to treat hepatocellular carcinoma

L. Ielasi et al.

DRUGS OF TODAY (2019)

Add to Collection

Review Oncology

Diagnostic and therapeutic potential of the gut microbiota in patients with early hepatocellular carcinoma

Francesca Romana Ponziani et al.

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2019)

Add to Collection

Review Oncology

Clinically relevant drug interactions with multikinase inhibitors: a review

Koen G. A. M. Hussaarts et al.

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2019)

Add to Collection

Review Oncology

Lenvatinib - A multikinase inhibitor for radioiodine-refractory differentiated thyroid cancer

Yvonne Hewett et al.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2018)

Add to Collection

Article Oncology

The outcome of sorafenib monotherapy on hepatocellular carcinoma with portal vein tumor thrombosis

Yuan-Hung Kuo et al.

INVESTIGATIONAL NEW DRUGS (2018)

Add to Collection

Article Medicine, Research & Experimental

Tutorial on Monoclonal Antibody Pharmacokinetics and Its Considerations in Early Development

Meric Ovacik et al.

CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2018)

Add to Collection

Review Pharmacology & Pharmacy

Host genetic profiling to increase drug safety in colorectal cancer from discovery to implementation

Erika Cecchin et al.

DRUG RESISTANCE UPDATES (2018)

Add to Collection

Article Pharmacology & Pharmacy

Differential effects of hepatic cirrhosis on the intrinsic clearances of sorafenib and imatinib by CYPs in human liver

Michael Murray et al.

EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2018)

Add to Collection

Article Oncology

Survival and tolerance to sorafenib in Child-Pugh B patients with hepatocellular carcinoma: a prospective study

Cassia Regina Guedes Leal et al.

INVESTIGATIONAL NEW DRUGS (2018)

Add to Collection

Article Medicine, General & Internal

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

Masatoshi Kudo et al.

LANCET (2018)

Add to Collection

Article Medicine, General & Internal

Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma

G. K. Abou-Alfa et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Review Pharmacology & Pharmacy

Clinical Pharmacokinetics and Pharmacodynamics of Cabozantinib

Steven A. Lacy et al.

CLINICAL PHARMACOKINETICS (2017)

Add to Collection

Review Pharmacology & Pharmacy

Clinical Pharmacokinetic and Pharmacodynamic Profile of Lenvatinib, an Orally Active, Small-Molecule, Multitargeted Tyrosine Kinase Inhibitor

Ziad Hussein et al.

EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS (2017)

Add to Collection

Article Medicine, General & Internal

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

Jordi Bruix et al.

LANCET (2017)

Add to Collection

Article Pharmacology & Pharmacy

Population pharmacokinetic meta-analysis of ramucirumab in cancer patients

Lisa O'Brien et al.

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2017)

Add to Collection

Article Oncology

Population pharmacokinetics of bevacizumab in cancer patients with external validation

Kelong Han et al.

CANCER CHEMOTHERAPY AND PHARMACOLOGY (2016)

Add to Collection

Article Pharmacology & Pharmacy

Bevacizumab Pharmacokinetics Influence Overall and Progression-Free Survival in Metastatic Colorectal Cancer Patients

Morgane Caulet et al.

CLINICAL PHARMACOKINETICS (2016)

Add to Collection

Article Pharmacology & Pharmacy

Effect of Renal and Hepatic Impairment on the Pharmacokinetics of Cabozantinib

Linh Nguyen et al.

JOURNAL OF CLINICAL PHARMACOLOGY (2016)

Add to Collection

Article Gastroenterology & Hepatology

Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study

Jorge A. Marrero et al.

JOURNAL OF HEPATOLOGY (2016)

Add to Collection

Article Medicine, Research & Experimental

Improving Oral Bioavailability of Sorafenib by Optimizing the Spring and Parachute Based on Molecular Interaction Mechanisms

Chengyu Liu et al.

MOLECULAR PHARMACEUTICS (2016)

Add to Collection

Review Gastroenterology & Hepatology

Treatment of hepatocellular carcinoma with portal venous tumor thrombosis: A comprehensive review

Kichang Han et al.

WORLD JOURNAL OF GASTROENTEROLOGY (2016)

Add to Collection

Article Oncology

Pharmacologic activity and pharmacokinetics of metabolites of regorafenib in preclinical models

Dieter Zopf et al.

CANCER MEDICINE (2016)

Add to Collection

Article Pharmacology & Pharmacy

Evaluation of the effect of food and gastric pH on the single-dose pharmacokinetics of cabozantinib in healthy adult subjects

Linh Nguyen et al.

JOURNAL OF CLINICAL PHARMACOLOGY (2015)

Add to Collection

Article Pharmacology & Pharmacy

Influence of Hepatic Impairment on Lenvatinib Pharmacokinetics Following Single-Dose Oral Administration

Robert Shumaker et al.

JOURNAL OF CLINICAL PHARMACOLOGY (2015)

Add to Collection

Article Pharmacology & Pharmacy

Effects of Ketoconazole on the Pharmacokinetics of Lenvatinib (E7080) in Healthy Participants

Robert Shumaker et al.

CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2015)

Add to Collection

Review Gastroenterology & Hepatology

Effective treatment strategies other than sorafenib for the patients with advanced hepatocellular carcinoma invading portal vein

Su Jong Yu et al.

WORLD JOURNAL OF HEPATOLOGY (2015)

Add to Collection

Article Pharmacology & Pharmacy

Lower Exposure and Faster Clearance of Bevacizumab in Gastric Cancer and the Impact of Patient Variables: Analysis of Individual Data from AVAGAST Phase III Trial

Kelong Han et al.

AAPS JOURNAL (2014)

Add to Collection

Article Pharmacology & Pharmacy

Effect of Rifampicin on the Pharmacokinetics of Lenvatinib in Healthy Adults

Robert C. Shumaker et al.

CLINICAL DRUG INVESTIGATION (2014)

Add to Collection

Article Pharmacology & Pharmacy

Evaluation of the effects of formulation and food on the pharmacokinetics of lenvatinib (E7080) in healthy volunteers

Robert Shumaker et al.

INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS (2014)

Add to Collection

Review Gastroenterology & Hepatology

Systemic Therapy for Hepatocellular Carcinoma: The Issue of Treatment Stage Migration and Registration of Progression Using the BCLC-Refined RECIST

Maria Reig et al.

SEMINARS IN LIVER DISEASE (2014)

Add to Collection

Article Endocrinology & Metabolism

Antitumor Activity of Lenvatinib (E7080): An Angiogenesis Inhibitor That Targets Multiple Receptor Tyrosine Kinases in Preclinical Human Thyroid Cancer Models

Osamu Tohyama et al.

JOURNAL OF THYROID RESEARCH (2014)

Add to Collection

Article Cell & Tissue Engineering

Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage

Yuji Yamamoto et al.

VASCULAR CELL (2014)

Add to Collection

Article Gastroenterology & Hepatology

Vascular Invasion in Hepatocellular Carcinoma

Yun-Hsuan Lee et al.

JOURNAL OF CLINICAL GASTROENTEROLOGY (2013)

Add to Collection

Article Medicine, Research & Experimental

Influence of FCGRT gene polymorphisms on pharmacokinetics of therapeutic antibodies

Christophe Passot et al.

MABS (2013)

Add to Collection

Article Oncology

Effect of increased body mass index (BMI) on time to tumour progression (TTP) in unresectable metastatic colorectal cancer (mCRC) patients treated with bevacizumab-based therapy

N. Faruk Aykan et al.

MEDICAL ONCOLOGY (2013)

Add to Collection

Article Biotechnology & Applied Microbiology

Soluplus-coated colloidal silica nanomatrix system for enhanced supersaturation and oral absorption of poorly water-soluble drugs

Min-Soo Kim

ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY (2013)

Add to Collection

Article Oncology

Saturable absorption of sorafenib in patients with solid tumors: a population model

Marilyne Hornecker et al.

INVESTIGATIONAL NEW DRUGS (2012)

Add to Collection

Article Gastroenterology & Hepatology

Portal hemodynamic effects of sorafenib in patients with advanced hepatocellular carcinoma: a prospective cohort study

Hisashi Hidaka et al.

JOURNAL OF GASTROENTEROLOGY (2012)

Add to Collection

Article Oncology

Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity

Scott M. Wilhelm et al.

INTERNATIONAL JOURNAL OF CANCER (2011)

Add to Collection

Article Pharmacology & Pharmacy

Bioavailability and pharmacokinetics of sorafenib suspension, nanoparticles and nanomatrix for oral administration to rat

Xue-qing Wang et al.

INTERNATIONAL JOURNAL OF PHARMACEUTICS (2011)

Add to Collection

Article Oncology

Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth

F. Michael Yakes et al.

MOLECULAR CANCER THERAPEUTICS (2011)

Add to Collection

Article Chemistry, Multidisciplinary

Functional and Clinical Evidence of the Influence of Sorafenib Binding to Albumin on Sorafenib Disposition in Adult Cancer Patients

Michel Tod et al.

PHARMACEUTICAL RESEARCH (2011)

Add to Collection

Article Oncology

Bevacizumab

Filis Kazazi-Hyseni et al.

ONCOLOGIST (2010)

Add to Collection

Review Oncology

Clinical pharmacokinetics of tyrosine kinase inhibitors

Nielka P. van Erp et al.

CANCER TREATMENT REVIEWS (2009)

Add to Collection

Article Chemistry, Analytical

Validation of an HPLC-UV method for sorafenib determination in human plasma and application to cancer patients in routine clinical practice

B. Blanchet et al.

JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2009)

Add to Collection

Article Oncology

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

Ann-Lii Cheng et al.

LANCET ONCOLOGY (2009)

Add to Collection

Article Oncology

Clinical pharmacokinetics of bevacizumab in patients with solid tumors

Jian-Feng Lu et al.

CANCER CHEMOTHERAPY AND PHARMACOLOGY (2008)

Add to Collection

Review Pharmacology & Pharmacy

Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction

Roger K. Verbeeck

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2008)

Add to Collection

Article Medicine, General & Internal

Sorafenib in advanced hepatocellular carcinoma

Josep M. Llovet et al.

NEW ENGLAND JOURNAL OF MEDICINE (2008)

Add to Collection

Article Oncology

E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition

Junji Matsui et al.

INTERNATIONAL JOURNAL OF CANCER (2008)

Add to Collection

Article Gastroenterology & Hepatology

Report of the 17th Nationwide Follow-up Survey of Primary Liver Cancer in Japan

Iwao Ikai et al.

HEPATOLOGY RESEARCH (2007)

Add to Collection

Article Oncology

Sorafenib for the treatment of advanced renal cell carcinoma

Robert C. Kane et al.

CLINICAL CANCER RESEARCH (2006)

Add to Collection

Article Oncology

Phase II study of sorafenib in patients with advanced hepatocellular carcinoma

Ghassan K. Abou-Alfa et al.

JOURNAL OF CLINICAL ONCOLOGY (2006)

Add to Collection

Article Oncology

Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics

C Lathia et al.

CANCER CHEMOTHERAPY AND PHARMACOLOGY (2006)

Add to Collection

Article Food Science & Technology

Oral administration of two probiotic strains, Lactobacillus gasseri CECT5714 and Lactobacillus coryniformis CECT5711, enhances the intestinal function of healthy adults

M Olivares et al.

INTERNATIONAL JOURNAL OF FOOD MICROBIOLOGY (2006)

Add to Collection

Article Oncology

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

SM Wilhelm et al.

CANCER RESEARCH (2004)

Add to Collection

Article Biochemistry & Molecular Biology

Tailoring in vitro selection for a picomolar affinity human antibody directed against vascular endothelial growth factor receptor 2 for enhanced neutralizing activity

D Lu et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2003)

Add to Collection

Article Oncology

Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibody affinity and biological activity

Z Zhu et al.

LEUKEMIA (2003)

Add to Collection

© Peeref 2019-2024. All rights reserved.